171 related articles for article (PubMed ID: 30898512)
21. Predictive factor for volume reduction of uterine fibroids after short-term use of ulipristal acetate.
Yun BS; Seong SJ; Jung YW; Kim ML; Bae HS; Kim MK; Shim SS
Eur J Obstet Gynecol Reprod Biol; 2018 May; 224():133-136. PubMed ID: 29602142
[TBL] [Abstract][Full Text] [Related]
22. Long-term treatment of uterine fibroids with ulipristal acetate ☆.
Donnez J; Vázquez F; Tomaszewski J; Nouri K; Bouchard P; Fauser BC; Barlow DH; Palacios S; Donnez O; Bestel E; Osterloh I; Loumaye E;
Fertil Steril; 2014 Jun; 101(6):1565-73.e1-18. PubMed ID: 24630081
[TBL] [Abstract][Full Text] [Related]
23. The place of selective progesterone receptor modulators in myoma therapy.
Donnez J; Donnez O; Courtoy GE; Dolmans MM
Minerva Ginecol; 2016 Jun; 68(3):313-20. PubMed ID: 26930390
[TBL] [Abstract][Full Text] [Related]
24. Ulipristal acetate: a novel pharmacological approach for the treatment of uterine fibroids.
Biglia N; Carinelli S; Maiorana A; D'Alonzo M; Lo Monte G; Marci R
Drug Des Devel Ther; 2014; 8():285-92. PubMed ID: 24591818
[TBL] [Abstract][Full Text] [Related]
25. [Applicability of selective progesterone receptor modulators in the treatment of uterine leiomyomata and their future role in the field of gynecology].
Brazert M; Korman MP; Pawelczyk LA
Ginekol Pol; 2013 Sep; 84(9):794-800. PubMed ID: 24191519
[TBL] [Abstract][Full Text] [Related]
26. Ulipristal acetate for the management of large uterine fibroids associated with heavy bleeding: a review.
Donnez J; Courtoy GE; Donnez O; Dolmans MM
Reprod Biomed Online; 2018 Aug; 37(2):216-223. PubMed ID: 29706284
[TBL] [Abstract][Full Text] [Related]
27. Effects of a novel estrogen-free, progesterone receptor modulator contraceptive vaginal ring on inhibition of ovulation, bleeding patterns and endometrium in normal women.
Brache V; Sitruk-Ware R; Williams A; Blithe D; Croxatto H; Kumar N; Kumar S; Tsong YY; Sivin I; Nath A; Sussman H; Cochon L; Miranda MJ; Reyes V; Faundes A; Mishell D
Contraception; 2012 May; 85(5):480-8. PubMed ID: 22176795
[TBL] [Abstract][Full Text] [Related]
28. Ulipristal acetate decreases transforming growth factor β3 serum and tumor tissue concentrations in patients with uterine fibroids.
Ciebiera M; Włodarczyk M; Wrzosek M; Słabuszewska-Jóźwiak A; Nowicka G; Jakiel G
Fertil Steril; 2018 Mar; 109(3):501-507.e2. PubMed ID: 29525690
[TBL] [Abstract][Full Text] [Related]
29. Ulipristal acetate--a review of the new therapeutic indications and future prospects.
Delev DP
Folia Med (Plovdiv); 2013; 55(3-4):5-10. PubMed ID: 24712276
[TBL] [Abstract][Full Text] [Related]
30. Ulipristal acetate for uterine fibroids: 2 years of real world experience in a UK hospital.
Woodhead N; Pounds R; Irani S; Pradhan P
J Obstet Gynaecol; 2018 Aug; 38(6):813-817. PubMed ID: 29526144
[TBL] [Abstract][Full Text] [Related]
31. Ulipristal acetate for use in moderate to severe symptoms of uterine fibroids.
Talaulikar VS; Manyonda I
Womens Health (Lond); 2014 Nov; 10(6):565-70. PubMed ID: 25482483
[TBL] [Abstract][Full Text] [Related]
32. Place of ulipristal acetate in the management of uterine fibroids: Preoperative treatment or sequential treatment?
Pourcelot AG; Capmas P; Fernandez H
J Gynecol Obstet Hum Reprod; 2017 Mar; 46(3):249-254. PubMed ID: 28403922
[TBL] [Abstract][Full Text] [Related]
33. Changes in proliferating and apoptotic markers of leiomyoma following treatment with a selective progesterone receptor modulator or gonadotropin-releasing hormone agonist.
Yun BS; Seong SJ; Cha DH; Kim JY; Kim ML; Shim JY; Park JE
Eur J Obstet Gynecol Reprod Biol; 2015 Aug; 191():62-7. PubMed ID: 26093349
[TBL] [Abstract][Full Text] [Related]
34. Effects of levonorgestrel-releasing IUS and progesterone receptor modulator PRM CDB-2914 on uterine leiomyomas.
Maruo T; Ohara N; Matsuo H; Xu Q; Chen W; Sitruk-Ware R; Johansson ED
Contraception; 2007 Jun; 75(6 Suppl):S99-103. PubMed ID: 17531625
[TBL] [Abstract][Full Text] [Related]
35. Histomorphological changes in endometriosis in a patient treated with ulipristal: A case report.
Bateman J; Bougie O; Singh S; Islam S
Pathol Res Pract; 2017 Jan; 213(1):79-81. PubMed ID: 27914766
[TBL] [Abstract][Full Text] [Related]
36. Ulipristal acetate therapy increases ultrasound features of adenomyosis: a good treatment given in an erroneous diagnosis of uterine fibroids.
Conway F; Morosetti G; Camilli S; Martire FG; Sorrenti G; Piccione E; Zupi E; Exacoustos C
Gynecol Endocrinol; 2019 Mar; 35(3):207-210. PubMed ID: 30382803
[TBL] [Abstract][Full Text] [Related]
37. Safety after extended repeated use of ulipristal acetate for uterine fibroids.
Fauser BC; Donnez J; Bouchard P; Barlow DH; Vázquez F; Arriagada P; Skouby SO; Palacios S; Tomaszewski J; Lemieszczuk B; William AR
PLoS One; 2017; 12(3):e0173523. PubMed ID: 28267814
[TBL] [Abstract][Full Text] [Related]
38. Effect of ulipristal acetate and mifepristone at emergency contraception dose on the embryo-endometrial attachment using an in vitro human trophoblastic spheroid and endometrial cell co-culture model.
Li HWR; Li YX; Li TT; Fan H; Ng EH; Yeung WS; Ho PC; Lee KF
Hum Reprod; 2017 Dec; 32(12):2414-2422. PubMed ID: 29121217
[TBL] [Abstract][Full Text] [Related]
39. Role of ethnicity in treating uterine fibroids with ulipristal acetate.
Murji A; Crosier R; Chow T; Ye XY; Shirreff L
Fertil Steril; 2016 Oct; 106(5):1165-1169. PubMed ID: 27336213
[TBL] [Abstract][Full Text] [Related]
40. Ulipristal acetate in the management of symptomatic uterine fibroids: facts and pending issues.
Pérez-López FR
Climacteric; 2015 Apr; 18(2):177-81. PubMed ID: 25390187
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
